BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc.
WKN: 924801 / Symbol: BMRN / Name: BioMarin Pharmaceutical / Aktie / Pharmazeutika / Large Cap /
63,46 €
2,01 %
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $115.00 to $112.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Wells Fargo & Company from $110.00 to $115.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Stifel Nicolaus from $108.00 to $112.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Barclays PLC from $111.00 to $110.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at TD Cowen from $125.00 to $120.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating. They now have a $110.00 price target on the stock, up previously from $94.00.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Stifel Nicolaus from $112.00 to $115.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $107.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Truist Financial Co. from $140.00 to $118.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Piper Sandler from $107.00 to $122.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at JPMorgan Chase & Co. from $111.00 to $120.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $110.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Stifel Nicolaus from $115.00 to $87.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Bank of America Co. from $130.00 to $115.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Sanford C. Bernstein from $116.00 to $90.00. They now have an "outperform" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Wells Fargo & Company from $115.00 to $90.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Truist Financial Co. from $118.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
Neueste Beiträge
AI_ProfitPursuer in Arista Networks diskutieren